Front Page

Blue Cross Medicare AdvantageSM wellness benefits
Researchers discover mutated gene that prevents diabetes
Medical ID bracelets can save your life
Get preferred pricing at these pharmacies
Save with generic drugs
Get a free workout booklet
Blue365 deal: Walkadoo

Fight diabetes with good nutrition
Tips for taking your medicine right
6 paths to a happier life
Get moving for better health
Beware of food-drug interactions
Antioxidants for good health
Protect your eyes from the sun
Is it more than a senior moment?
Tips for bolstering your memory
How to get more for your vacation bucks
Readers' stories of retiring and finding themselves anew
Drug companies collaborate on research
China's Terra Cotta Warriors come to Indianapolis
'LifeTimes' wins design award
Learn about Hope Paige, maker of fashionable medical ID bracelets
Learn about HealthWays, creator of the Walkadoo social walking program
BCBSNM social responsibility report
Your letters to "LifeTimes"
Play our 'Mystery Game'
Crossword puzzle
Sudoku puzzle
Word search puzzle
Medicare Basics
Recent News
Current Issue
Previous Issues
About LifeTimes Newsletter
Sign up for LifeTimes email updates

  facebook twitter youtube
  Learn more

Share |
Latest News

Mutated gene cuts Type 2 diabetes risk by 65 percent

The discovery of a human gene mutation that decreases the risk of developing Type 2 diabetes by two-thirds may be the key to a promising new gene-based approach to treating or preventing diabetes.

Researchers at the Broad Institute and Massachusetts General Hospital led an international team of researchers in a study looking at the impact of a single gene mutation on diabetes risk.  The team analyzed the genomes of 150,000 people in Sweden, Finland, and Iceland and found that those with the mutant gene SLC30A8 had a 65 percent lower risk of developing type 2 diabetes, regardless of age, weight, or other factors typically associated with diabetes.

It's the first time mutated genes have proven helpful in diabetes research, says Louis Philipson, director of the University of Chicago's Kovler Diabetes Center. "For drug development, this is very powerful." Philipson was not involved in the study.

Type 2 diabetes results when the body can no longer produce enough insulin on its own, but those with the mutation seemed resistant to developing diabetes. Test subjects were fat and skinny, young and old, healthy and sick, exercisers and couch potatoes. Many drank and smoked. Oddly, none of that mattered in the folks with the mutation.

All that did matter was that those with the rare SLC30A8 mutation were less likely to develop the disease.  The exact way the altered gene exerts this effect is unclear.

Many scientists doubted the study could be valid, since the same mutation in mice lab tests led to the opposite result – mice made less insulin and were more likely to develop diabetes. This mystery is yet to be solved. But researchers say human findings warrant more study that could lead to a drug to prevent Type 2 diabetes in a wide range of adults. It could be 10 or more years away, they caution.

The project was published in the March 2014 issue of "Nature Genetics." Drug firms Pfizer and Amgen and several universities cooperated. The National Institutes of Health funded one academic study.

Learn how 10 drugs companies are working together to develop new drugs faster and more cost effectively.